The Effects of Radioiodine Therapy on the Recovery of Parathyroid Function in Patients with Protracted Hypoparathyroidism after Total Thyroidectomy for Papillary Thyroid Carcinoma.

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2023-12-31 Epub Date: 2022-11-21 DOI:10.1080/08941939.2022.2146239

Munire Abuduwaili, Wusiman Baidula, Baoying Xia, Zhujuan Wu, Ziwei Chen, Zhichao Xing, Anping Su

{"title":"The Effects of Radioiodine Therapy on the Recovery of Parathyroid Function in Patients with Protracted Hypoparathyroidism after Total Thyroidectomy for Papillary Thyroid Carcinoma.","authors":"Munire Abuduwaili, Wusiman Baidula, Baoying Xia, Zhujuan Wu, Ziwei Chen, Zhichao Xing, Anping Su","doi":"10.1080/08941939.2022.2146239","DOIUrl":null,"url":null,"abstract":"Background: To determine the effect of 131I treatment on postoperative parathyroid function and the timing of recovery of parathyroid function (RPF) in patients with protracted hypoPT.Methods: 260 patients with papillary thyroid cancer (PTC) were retrospectively analyzed, including 166 patients treated with radioactive iodine-131 (131I) classified into the 131I group and 94 patients without 131I treatment classified into the control group. Data on clinicopathological characteristics, demographics, dose and interval time of 131I treatment, number of parathyroid glands remaining in situ (PGRIS), occurrence of hypoPT, duration of RPF, preoperative and postoperative levels of Ca and PTH were collected.Results: The patients in the 131I group showed a higher persistent hypoPT rate than those in the control group (p = 0). The PGRIS and total number of PG were significantly higher in patients who recovered from protracted HypoPT (p = 0.02; p = 0.03). PGRIS and 131I treatment [1 ∼ 2 VS 0, p = 0.03, OR 3.19; 3 ∼ 4 VS 0, p = 0.02, OR3.62; p = 0.02, OR 1.98, respectively] were independent factors influencing postoperative persistent hypoPT. The timing of RPF differed significantly for patients in the control group compared to those in the 131I group [p = 0.00].Conclusions: We found that 131I treatment significantly prolonged the RPF of patients with protracted hypoPT and caused late RPF (even beyond 12 months). The diagnosis of \"permanent\" hypoPT should be cautiously made at least 12 months after surgery, especially in patients who receive 131I treatment.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"1-9"},"PeriodicalIF":4.7000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08941939.2022.2146239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To determine the effect of 131I treatment on postoperative parathyroid function and the timing of recovery of parathyroid function (RPF) in patients with protracted hypoPT.

Methods: 260 patients with papillary thyroid cancer (PTC) were retrospectively analyzed, including 166 patients treated with radioactive iodine-131 (131I) classified into the 131I group and 94 patients without 131I treatment classified into the control group. Data on clinicopathological characteristics, demographics, dose and interval time of 131I treatment, number of parathyroid glands remaining in situ (PGRIS), occurrence of hypoPT, duration of RPF, preoperative and postoperative levels of Ca and PTH were collected.

Results: The patients in the 131I group showed a higher persistent hypoPT rate than those in the control group (p = 0). The PGRIS and total number of PG were significantly higher in patients who recovered from protracted HypoPT (p = 0.02; p = 0.03). PGRIS and 131I treatment [1 ∼ 2 VS 0, p = 0.03, OR 3.19; 3 ∼ 4 VS 0, p = 0.02, OR3.62; p = 0.02, OR 1.98, respectively] were independent factors influencing postoperative persistent hypoPT. The timing of RPF differed significantly for patients in the control group compared to those in the 131I group [p = 0.00].

Conclusions: We found that 131I treatment significantly prolonged the RPF of patients with protracted hypoPT and caused late RPF (even beyond 12 months). The diagnosis of "permanent" hypoPT should be cautiously made at least 12 months after surgery, especially in patients who receive 131I treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

放射性碘疗法对甲状旁腺乳头状癌全甲状腺切除术后长期甲状旁腺功能减退患者甲状旁腺功能恢复的影响

背景：旨在确定131I治疗对术后甲状旁腺功能的影响以及甲状旁腺功能（RPF）恢复的时间：方法：对260例甲状腺乳头状癌（PTC）患者进行回顾性分析，包括166例接受放射性碘131（131I）治疗的患者（131I组）和94例未接受131I治疗的患者（对照组）。研究收集了临床病理特征、人口统计学、131I治疗剂量和间隔时间、甲状旁腺原位残留数量（PGRIS）、PT过低发生率、RPF持续时间、术前和术后Ca和PTH水平等数据：131I组患者的持续PT过低率高于对照组（P = 0）。PGRIS和PG总数在从持久性低PT中恢复的患者中明显较高（P = 0.02；P = 0.03）。PGRIS 和 131I 治疗[分别为 1 ∼ 2 VS 0，p = 0.03，OR 3.19；3 ∼ 4 VS 0，p = 0.02，OR 3.62；p = 0.02，OR 1.98]是影响术后持续低PT的独立因素。对照组患者与 131I 组患者的 RPF 发生时间差异显著[p = 0.00]：我们发现，131I 治疗明显延长了久治不愈的肺功能减退患者的 RPF，并导致晚期 RPF（甚至超过 12 个月）。对 "永久性 "PT 低减的诊断应在术后至少 12 个月后谨慎做出，尤其是接受 131I 治疗的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.